BioNTech presents positive phase 1/2 data for CAR-T cell therapy candidate
"The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac."Not sure why this is all that interesting to HN.  It's a very early trial and the outcome is "encouraging".Other than a proof of concept that it might work, there is nothing here.